Compare WY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WY | BIIB |
|---|---|---|
| Founded | 1900 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | WY | BIIB |
|---|---|---|
| Price | $21.69 | $181.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 23 |
| Target Price | $29.78 | ★ $176.48 |
| AVG Volume (30 Days) | ★ 6.0M | 1.9M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.46 | ★ 10.97 |
| Revenue | $7,072,000,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $0.04 | $3.61 |
| Revenue Next Year | $3.97 | N/A |
| P/E Ratio | $47.48 | ★ $16.52 |
| Revenue Growth | N/A | ★ 4.77 |
| 52 Week Low | $21.16 | $110.04 |
| 52 Week High | $32.70 | $185.17 |
| Indicator | WY | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 72.92 |
| Support Level | $21.22 | $174.53 |
| Resistance Level | $22.47 | $182.94 |
| Average True Range (ATR) | 0.51 | 5.22 |
| MACD | 0.05 | 0.25 |
| Stochastic Oscillator | 38.97 | 83.54 |
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).